SCHEMBL10243636

SCHEMBL10243636

CCOc1nc(NCc2ccco2)nc(Nc2ccccc2)n1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.79
MAPK1 P28482 6/20 0.79
KMT2A Q03164 5/20 0.79
NPSR1 Q6W5P4 4/20 0.79
ALDH1A1 P00352 4/20 0.79
MEN1 O00255 3/20 0.79
KCNH3 Q9ULD8 3/20 0.76
SMN1; SMN2 Q16637 3/20 0.72
HTT P42858 2/20 0.66
EGFR P00533 1/20 0.57
KDM4E B2RXH2 3/20 0.56
RECQL P46063 2/20 0.54
TDP1 Q9NUW8 3/20 0.54
GAA P10253 1/20 0.53
LMNA P02545 1/20 0.51
XBP1 P17861 1/20 0.51
GPR55 Q9Y2T6 1/20 0.51
POLB P06746 1/20 0.50
BLM P54132 1/20 0.50
SOS1 Q07889 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391101 0.90 MAPT (0.78) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1390720 0.90 MAPT (0.78) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1390856 0.90 MAPT (0.78) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1390779 0.89 MAPT (1.00) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1391723 0.88 MAPT (0.67) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1391195 0.88 MAPT (0.69) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1390914 0.88 MAPT (0.75) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL5015555 0.87 KCNH3 (1.00) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1391275 0.87 MAPT (0.74) MAPTMAPK1KMT2ANPSR1ALDH1A1
SCHEMBL1391106 0.87 MAPT (0.74) MAPTMAPK1KMT2ANPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS MAPT 3654/4885MAPK1 2676/4885KMT2A 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.